Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors

被引：41

作者：

Nurwidya, Fariz ^{[1
]}

Takahashi, Fumiyuki ^{[1
]}

Murakami, Akiko ^{[1
]}

Kobayashi, Isao ^{[1
]}

Kato, Motoyasu ^{[1
]}

Shukuya, Takehito ^{[1
]}

Tajima, Ken ^{[1
]}

Shimada, Naoko ^{[1
]}

Takahashi, Kazuhisa ^{[1
]}

机构：

[1] Juntendo Univ, Grad Sch Med, Dept Resp Med, Bunkyo Ku, Tokyo 1138421, Japan

来源：

RESPIRATORY INVESTIGATION | 2014年 / 52卷 / 02期

关键词：

Acquired resistance; Epidermal growth factor receptor (EGFR); Non-small cell lung cancer (NSCLC); Tyrosine kinase inhibitors;

D O I：

10.1016/j.resinv.2013.07.007

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Activation of epidermal growth factor receptor (EGFR) triggers anti-apoptotic signaling, proliferation, angiogenesis, invasion, metastasis, and drug resistance, which leads to development and progression of human epithelial cancers, including non-small cell lung cancer (NSCLC). Inhibition of EGFR by tyrosine kinase inhibitors such as gefitinib and erlotinib has provided a new hope for the cure of NSCLC patients. However, acquired resistance to gefitinib and erlotinib via EGFR-mutant NSCLC has occurred through various molecular mechanisms such as T790M secondary mutation, MET amplification, hepatocyte growth factor (HGF) overexpression, PTEN downregulation, epithelial-mesenchymal transition (EMT), and other mechanisms. This review will discuss the biology of receptor tyrosine kinase inhibition and focus on the molecular mechanisms of acquired resistance to tyrosine kinase inhibitors of EGFR-mutant NSCLC. (C) 2013 The Japanese Respiratory Socity. Published by Elsevier B.V. All rights reserved.

引用

页码：82 / 91

页数：10

共 113 条

[51] Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib [J].

Kwak, EL ;

Sordella, R ;

Bell, DW ;

Godin-Heymann, N ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Driscoll, DR ;

Fidias, P ;

Lynch, TJ ;

Rabindran, SK ;

McGinnis, JP ;

Wissner, A ;

Sharma, SV ;

Isselbacher, KJ ;

Settleman, J ;

Haber, DA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (21) :7665-7670

[52] Noncovalent Wild-type-Sparing Inhibitors of EGFR T790M [J].

Lee, Ho-June ;

Schaefer, Gabriele ;

Heffron, Timothy P. ;

Shao, Lily ;

Ye, Xiaofen ;

Sideris, Steve ;

Malek, Shiva ;

Chan, Emily ;

Merchant, Mark ;

La, Hank ;

Ubhayakar, Savita ;

Yauch, Robert L. ;

Pirazzoli, Valentina ;

Politi, Katerina ;

Settleman, Jeff .

CANCER DISCOVERY, 2013, 3 (02) :168-181

[53] Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib [J].

Lemos, C. ;

Kathmann, I. ;

Giovannetti, E. ;

Calhau, C. ;

Jansen, G. ;

Peters, G. J. .

BRITISH JOURNAL OF CANCER, 2009, 100 (07) :1120-1127

[54] Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients [J].

Li, Jing ;

Cusatis, George ;

Brahmer, Julie ;

Sparreboom, Alex ;

Robey, Robert W. ;

Bates, Susan E. ;

Hidalgo, Manuel ;

Baker, Sharyn D. .

CANCER BIOLOGY & THERAPY, 2007, 6 (03) :432-438

[55] Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis [J].

Li, Y. ;

Ye, X. ;

Tan, C. ;

Hongo, J-A ;

Zha, J. ;

Liu, J. ;

Kallop, D. ;

Ludlam, M. J. C. ;

Pei, L. .

ONCOGENE, 2009, 28 (39) :3442-3455

[56] Quantitation of the Effect of ErbB2 on Epidermal Growth Factor Receptor Binding and Dimerization [J].

Li, Yu ;

Macdonald-Obermann, Jennifer ;

Westfall, Corey ;

Piwnica-Worms, David ;

Pike, Linda J. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (37) :31116-31125

[57] Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer [J].

Linger, R. M. A. ;

Cohen, R. A. ;

Cummings, C. T. ;

Sather, S. ;

Migdall-Wilson, J. ;

Middleton, D. H. G. ;

Lu, X. ;

Baron, A. E. ;

Franklin, W. A. ;

Merrick, D. T. ;

Jedlicka, P. ;

DeRyckere, D. ;

Heasley, L. E. ;

Graham, D. K. .

ONCOGENE, 2013, 32 (29) :3420-3431

[58] Functional expression and mutations of c-met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer [J].

Ma, PC ;

Jagadeeswaran, R ;

Jagadeesh, S ;

Tretiakova, MS ;

Nallasura, V ;

Fox, EA ;

Hansen, M ;

Schaefer, E ;

Naoki, K ;

Lader, A ;

Richards, W ;

Sugarbaker, D ;

Husain, AN ;

Christensen, JG ;

Salgia, R .

CANCER RESEARCH, 2005, 65 (04) :1479-1488

[59] Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer [J].

Miller, VA ;

Kris, WG ;

Shah, N ;

Patel, J ;

Azzoli, C ;

Gomez, J ;

Krug, LM ;

Pao, W ;

Rizvi, N ;

Pizzo, B ;

Tyson, L ;

Venkatraman, E ;

Ben-Porar, L ;

Memoli, N ;

Zakowski, M ;

Rusch, V ;

Heelan, RT .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1103-1109

[60] Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial [J].

Miller, Vincent A. ;

Hirsh, Vera ;

Cadranel, Jacques ;

Chen, Yuh-Min ;

Park, Keunchil ;

Kim, Sang-We ;

Zhou, Caicun ;

Su, Wu-Chou ;

Wang, Mengzhao ;

Sun, Yan ;

Heo, Dae Seog ;

Crino, Lucio ;

Tan, Eng-Huat ;

Chao, Tsu-Yi ;

Shahidi, Mehdi ;

Cong, Xiuyu Julie ;

Lorence, Robert M. ;

Yang, James Chih-Hsin .

LANCET ONCOLOGY, 2012, 13 (05) :528-538

← 1 2 3 4 5 6 7 8 9 10 →